Gastrointestinal Diseases: Clinical Trials

2,535 trials for Gastrointestinal Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1252 completed, 462 unknown, 282 recruiting, 248 terminated. 2535 Phase 3, 405 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32535Completed 1252, Unknown 462, Recruiting 282, Terminated 248, Active not recruiting 130, Not yet recruiting 84, Withdrawn 64, Enrolling by invitation 8, Suspended 5
Phase 2405Completed 149, Unknown 100, Recruiting 57, Terminated 46, Active not recruiting 19, Not yet recruiting 16, Withdrawn 13, Enrolling by invitation 4, Suspended 1

Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases

Trials (filtered) newest first · largest first

All 2,535 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Methadone as an Alternative Treatment for Children Underdoing HSCT
PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia
Phase 3SuspendedUniversity of Texas Southwestern Medical Center602028-01-012025-10-23
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Piperacillin/Tazobactam Versus Ceftriaxone and Metronidazole for Children With Perforated Appendicitis
Piperacillin/Tazobactam, Ceftriaxone + Metronidazole - Appendicitis Perforated, Appendectomy, Laparoscopic
Phase 3Not yet recruitingMcMaster Children's Hospital1802027-04-012026-10-09
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma
Phase 3RecruitingCity of Hope Medical Center1292027-01-042026-11-05
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
Tislelizumab - Esophageal Cancer
Phase 3Not yet recruitingAsan Medical Center1722026-12-312026-10-29
Nitazoxanide for Treatment of Cryptosporidium in Children
Nitazoxanide, Placebo - Cryptosporidiosis
Phase 3Not yet recruitingJohns Hopkins Bloomberg School of Public Health4802026-12-302026-09-28
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection
SYS6010, SG001, SG001 placebo-mimicking - Esophageal Squamous Cell Carcinoma
Phase 3Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.5852026-12-302026-11-09
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Apatinib Mesylate Tablets - Gastric Cancer, Surgery
Phase 3Not yet recruitingFujian Medical University1182026-12-252026-01-02
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer
Phase 3RecruitingExelixis6002026-12-182026-11-12
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
Dostarlimab - Neoplasms, Rectal
Phase 3Not yet recruitingGlaxoSmithKline1002026-12-172026-11-16
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis
Phase 3RecruitingHua Huang, MD, PhD1702026-12-012026-10-16
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
Rifaximin (drug), Placebo - Bloating, Rifaximin
Phase 3Not yet recruitingMahidol University782026-12-012026-10-27
Effects of Butyrate Enemas on Postoperative Intestinal Motility Disorders in Hirschsprung's Disease
Sodium Butyrate, routine management - Hirschsprung's Disease
Phase 3Not yet recruitingAssistance Publique Hopitaux De Marseille582026-11-012026-09-10
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer
Phase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.3682026-11-012026-11-03
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
Rilogrotug, Placebo - Cachexia; Cancer, Cachexia
Phase 2 / Phase 3Not yet recruitingAVEO Pharmaceuticals, Inc.9502026-11-012026-10-28
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer
Phase 3Not yet recruitingSir Run Run Shaw Hospital2102026-10-252026-10-28
Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis
Nitazoxanide (NTZ) - Ulcerative Colitis (UC)
Phase 2 / Phase 3RecruitingTanta University442026-10-252026-11-09
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR
Phase 3Not yet recruitingFudan University4802026-10-152026-10-16
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
DWP14012 40mg (Fexuprazan), Lansoprazole 30mg - Gastric Ulcer
Phase 3Not yet recruitingDaewoong Pharmaceutical Co. LTD.3842026-10-152026-07-28

Showing 20 of 2535. Sign in to see all of them.

Narrower conditions

Colorectal Neoplasms (522)  ·  Stomach Neoplasms (301)  ·  Rectal Neoplasms (246)  ·  Crohn Disease (238)  ·  Colonic Neoplasms (237)  ·  Colitis, Ulcerative (223)  ·  Esophageal Neoplasms (133)  ·  Gastroesophageal Reflux (116)  ·  Inflammatory Bowel Diseases (97)  ·  Esophageal Squamous Cell Carcinoma (80)  ·  Irritable Bowel Syndrome (71)  ·  Neoplasm Metastasis (70)  ·  Neoplasms (63)  ·  Gastroenteritis (47)

Broader conditions

Digestive System Diseases (2506)  ·  Intestinal Diseases (1609)  ·  Digestive System Neoplasms (1322)  ·  Neoplasms (1309)  ·  Neoplasms by Site (1309)  ·  Gastrointestinal Neoplasms (1296)  ·  Colonic Diseases (970)  ·  Intestinal Neoplasms (801)  ·  Rectal Diseases (737)  ·  Gastroenteritis (630)  ·  Pathological Conditions, Signs and Symptoms (478)  ·  Esophageal Diseases (412)  ·  Stomach Diseases (407)  ·  Inflammatory Bowel Diseases (363)

Interventions

Fluorouracil (263)  ·  Oxaliplatin (228)  ·  Leucovorin (199)  ·  Capecitabine (183)  ·  Irinotecan (123)  ·  Bevacizumab (115)  ·  Cisplatin (97)  ·  Radiotherapy (68)  ·  Cetuximab (63)  ·  Paclitaxel (61)  ·  Mesalamine (59)  ·  Folfox protocol (55)  ·  Esomeprazole (49)  ·  Drug Therapy (47)  ·  Docetaxel (44)

Sponsors

Takeda (56)  ·  AstraZeneca (49)  ·  Sun Yat-sen University (49)  ·  Fudan University (45)  ·  Merck Sharp & Dohme LLC (33)  ·  Hoffmann-La Roche (31)  ·  Shire (31)  ·  Janssen Research & Development, LLC (29)  ·  AbbVie (28)  ·  Chinese University of Hong Kong (26)  ·  Alliance for Clinical Trials in Oncology (25)  ·  National Cancer Institute (NCI) (24)  ·  Bausch Health Americas, Inc. (21)  ·  Assistance Publique - Hôpitaux de Paris (20)  ·  Pfizer (20)

Countries

United States (765)  ·  China (580)  ·  France (433)  ·  Germany (413)  ·  Canada (411)  ·  Italy (367)  ·  United Kingdom (354)  ·  South Korea (343)  ·  Belgium (333)  ·  Spain (330)  ·  Poland (320)  ·  Japan (292)  ·  Netherlands (269)  ·  Australia (265)  ·  Hungary (220)

Top investigators

Norman Wolmark, MD (9)

Results publications

PMID 36306483, PMID 29380251, PMID 32445184, PMID 19735233, PMID 31268130, PMID 33356421, PMID 37368103, PMID 40341124, PMID 40357993, PMID 21129076, PMID 30679026, PMID 31378656, PMID 20195905, PMID 20526599, PMID 21997132, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32085892, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36208720, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37310167, PMID 37402275, PMID 37560161, PMID 38096402, PMID 38310565, PMID 38425446, PMID 40013523, PMID 41264726, PMID 41763462, PMID 23451835, PMID 24118079, PMID 25996351, PMID 26049686

NIH funding

2023 (50), 2017 (33), 2015 (28), 2025 (22), 2016 (21), 2018 (21), 2019 (18), 2014 (17), 2009 (12), 2008 (11), 2004 (10), U10CA031946 (9), 2005 (6), U10CA032102 (6), U10CA012027 (5)